Form 4: BMY SVP & Controller Holzer's Equity Transactions

Bristol-Myers Squibb's SVP and Controller, Phil M. Holzer, reported routine acquisitions and dispositions of company common stock and derivative securities related to compensation plans.

Summary

• Phil M. Holzer, SVP and Controller of Bristol-Myers Squibb Co. (BMY), reported multiple transactions involving the company's common stock and derivative securities on March 10, 2026.
• Acquired a total of 6,191 shares of common stock through the vesting of market share units (811 shares from a 2022 grant, 768 shares from a 2023 grant) and the distribution of performance shares (4,612 shares from the 2023-2025 Long-Term Performance Award).
• Disposed of a total of 3,796 shares of common stock, comprising 2,438 shares withheld for tax payments at $60.13 per share and 1,358 shares due to downward adjustments from performance factors.
• Beneficial ownership of common stock increased by 2,395 shares, from an inferred 14,967 shares to 17,362 shares following these transactions.
• Acquired 5,031 new market share units and 7,547 new performance shares, both scheduled to cliff vest on March 10, 2029.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, reflecting routine executive compensation activities. The vesting of awards and new grants indicate ongoing executive alignment, though performance factor adjustments suggest some targets were not fully met.

Positives

• Phil M. Holzer's beneficial ownership of common stock increased by 2,395 shares, demonstrating continued equity alignment with the company.
• The acquisition of 5,031 new market share units and 7,547 new performance shares indicates ongoing long-term incentive alignment with company performance.

Negatives

• A total of 2,438 shares were disposed of for tax payments at a price of $60.13 per share.
• A total of 1,358 shares were adjusted downwards due to performance factors, indicating that the performance targets for some awards were not fully met or resulted in a lower payout factor.

Future Outlook

The filing indicates a continued long-term incentive program for executives, with new market share units and performance shares granted on March 10, 2026, scheduled to vest on March 10, 2029, subject to performance certification by the Board.

Industry Context

StockSavvy.ai notes that these transactions are typical for executive compensation structures in the pharmaceutical industry, often involving a mix of time-based and performance-based equity awards to align executive interests with long-term shareholder value.

Comparison to Industry Standards

• These types of equity awards, including market share units and performance shares with payout factors tied to stock price performance and relative total shareholder return (rTSR), are standard practice for executive compensation in large-cap pharmaceutical companies like Pfizer, Merck, and Johnson & Johnson.
• The use of a rTSR floor feature, as described for the market share units, is a sophisticated mechanism designed to provide a minimum payout even if the company's stock price declines, provided it outperforms our peers based on their TSR percentile rank, which is a common feature in competitive executive compensation packages.

Related Party Transactions

• The transactions involve the company's SVP and Controller, Phil M. Holzer, acquiring and disposing of company stock and derivative securities as part of his compensation plan.

Stakeholder Impact

• Shareholders: The transactions represent routine executive compensation, aligning management's interests with shareholder value through equity ownership. The disposition of shares for tax purposes is a common occurrence and does not indicate a lack of confidence.
• Employees: The compensation structure for a senior executive may reflect broader compensation philosophies within the company.

Next Steps

• Certification of performance results by the Board for the market share units and performance shares vesting on March 10, 2029.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation transactions, including the vesting of equity awards and subsequent tax-related dispositions, alongside new grants. Such activities are standard and generally do not provide new fundamental information to warrant a change in investment thesis. The slight increase in beneficial ownership post-transactions, coupled with new long-term grants, suggests continued executive alignment, but the overall impact on the company's valuation or strategic direction is negligible. Therefore, a 'hold' recommendation is appropriate as this filing does not present a catalyst for significant price movement.

Keywords

Bristol-Myers Squibb, BMY, SEC Form 4, Insider Trading, Stock Transactions, Executive Compensation, Market Share Units, Performance Shares, Equity Awards, Phil M. Holzer